Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ben Tre Pharmaceutical JSCSTC:DBT +0.38%14 3-Year Share Buyback Ratio is 0.00 as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 646 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks worse than 154798.61% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Ben Tre Pharmaceutical JSC's current 3-Year Share Buyback Ratio was 0.00%.
The historical rank and industry rank for Ben Tre Pharmaceutical JSC's 3-Year Share Buyback Ratio or its related term are showing as below:
During the past 0 years, Ben Tre Pharmaceutical JSC's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was 0.00%. And the median was 0.00%.
STC:DBT's 3-Year Share Buyback Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: -2 * Ranked among companies with meaningful 3-Year Share Buyback Ratio only.
Ben Tre Pharmaceutical JSC (STC:DBT) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Ben Tre Pharmaceutical JSC 3-Year Share Buyback Ratio Related Terms
STC:DBT vs ZTS, UTHR, VTRS: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ben Tre Pharmaceutical JSC 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Ben Tre Pharmaceutical JSC's 3-Year Share Buyback Ratio falls into.
Ben Tre Pharmaceutical JSC 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.00 mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a 3-Year Share Buyback Ratio of 0.00 as of . 20. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Ben Tre Pharmaceutical JSC and its competitors. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 646 companies in the Drug Manufacturers industry.
Is Ben Tre Pharmaceutical JSC's 3-Year Share Buyback Ratio too high?
Ben Tre Pharmaceutical JSC's current 3-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 646 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's 3-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 646 companies for 3-Year Share Buyback Ratio. This places Ben Tre Pharmaceutical JSC in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Ben Tre Pharmaceutical JSC and its competitors. Ben Tre Pharmaceutical JSC's current 3-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current 3-Year Share Buyback Ratio of 0.00. The current 3-Year Share Buyback Ratio is 0.00. Ben Tre Pharmaceutical JSC's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current 3-Year Share Buyback Ratio is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
14GF Score
Get the complete analysis for STC:DBT
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DBT has been successfully added to your 
